FDMT Heads Into Earnings With a High Short Bar to Clear

4D Molecular Therapeutics reports today with short sellers holding a meaningful position — but the borrow market suggests conviction is limited rather than extreme.

Short interest runs at roughly 20.5% of the free float, with about 11.7 million shares short. That is an elevated level for a clinical-stage biotech. Yet the short interest has been falling sharply: it is down nearly 16% over the past month, retreating from around 14.6 million shares in early July. The borrow market reinforces this picture. Availability is loose at over 320%, meaning roughly three shares are available to borrow for every one already lent — well above the threshold that would signal short-seller crowding. Cost to borrow has eased about 25% in the past week to a negligible 0.54%. The ORTEX short score, while elevated at 73.5, is consistent with a stock where short sellers have been reducing, not building, exposure heading into the catalyst. Positioning looks cautious rather than aggressive.

Options tell a more defensive story as earnings arrive. The put/call ratio jumped to 0.105 on August 13, more than two standard deviations above its 20-day average of 0.073. That is a notable spike for a name where calls have overwhelmingly dominated the options market all year — the 52-week low PCR was 0.029, reflecting persistent bullish options bias. The sudden step-up in put activity against that backdrop is worth noting. The stock closed at $11.65 on August 13, down 1.9% on the day but up 10.4% on the week, suggesting the run-up has prompted some hedging. Peers were broadly positive on the week — SANA and ABSI gained 7.4% and 13.1% respectively — making the single-day dip in FDMT slightly divergent from the group.

The bull case rests on 4D-150, the company's gene therapy targeting wet AMD and diabetic macular edema, which analysts have modeled for substantial peak sales. The analyst consensus remains firmly constructive — every recent rating is a Buy or equivalent, and B. Riley Securities initiated with a $37 target as recently as July 31. The mean target of $29.20 implies roughly 150% upside from the current price, a gap that reflects genuine optimism about 4D-150's clinical differentiation and treatment burden reduction relative to standard-of-care. The bear case is equally familiar in gene therapy: manufacturing complexity, regulatory execution risk, and the absence of any commercial revenue to anchor valuation. Jefferies assumed coverage in March and trimmed its target sharply from $40 to $21, a dissenting signal in an otherwise bullish consensus. Insider behavior has tilted the other way — CEO David Kirn has sold shares consistently throughout June and July, netting roughly $2.6 million over the past 90 days. Those sales were made at prices between $10 and $13, close to current levels, though the pace has not been unusual for a founder managing a concentrated position in a pre-revenue name. Institutional ownership is broad: Janus Henderson, RA Capital, BlackRock, and Novo Holdings each hold meaningful stakes, providing a relatively stable shareholder base.

Post-earnings history for FDMT is volatile. A June 2026 readout produced an 11.4% one-day gain and a 34% five-day follow-through. A May 2026 event went the other way, with the stock falling 14.7% the day after and extending losses to 12.3% over five days. The print today will test whether the modest short covering of the past month was well-timed optimism or premature relief — and whether the spike in put activity was hedging by existing bulls or a sign that sentiment is shifting ahead of new clinical or financial disclosures.